UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Primary hyperparathyroidism: Diagnosis, differential diagnosis, and evaluation

Authors
Ghada El-Hajj Fuleihan, MD, MPH
Shonni J Silverberg, MD
Section Editor
Clifford J Rosen, MD
Deputy Editor
Jean E Mulder, MD

INTRODUCTION

The diagnosis of hyperparathyroidism is usually first suspected because of the finding of an elevated serum calcium concentration. If hypercalcemia is confirmed on a repeat sample, all of its causes should be considered (table 1). (See "Etiology of hypercalcemia".)

The serum parathyroid hormone (PTH) concentration should then be measured using a two-site immunoradiometric sandwich assay. The diagnosis of primary hyperparathyroidism (PHPT) is usually made by finding a PTH concentration that is frankly elevated or within the normal range but inappropriately normal given the patient's hypercalcemia (figure 1).

The diagnosis, differential diagnosis, and evaluation of PHPT will be discussed here. Other aspects of PHPT are reviewed elsewhere.

(See "Primary hyperparathyroidism: Clinical manifestations".)

(See "Primary hyperparathyroidism: Management".)

                          

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Wed Sep 30 00:00:00 GMT+00:00 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Silverberg SJ, Lewiecki EM, Mosekilde L, et al. Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009; 94:351.
  2. Lowe H, McMahon DJ, Rubin MR, et al. Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab 2007; 92:3001.
  3. Silverberg SJ, Clarke BL, Peacock M, et al. Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 2014; 99:3580.
  4. Silverberg SJ, Bilezikian JP. Evaluation and management of primary hyperparathyroidism. J Clin Endocrinol Metab 1996; 81:2036.
  5. Glendenning P, Gutteridge DH, Retallack RW, et al. High prevalence of normal total calcium and intact PTH in 60 patients with proven primary hyperparathyroidism: a challenge to current diagnostic criteria. Aust N Z J Med 1998; 28:173.
  6. Eastell R, Brandi ML, Costa AG, et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 2014; 99:3570.
  7. Silverberg SJ, Gao P, Brown I, et al. Clinical utility of an immunoradiometric assay for parathyroid hormone (1-84) in primary hyperparathyroidism. J Clin Endocrinol Metab 2003; 88:4725.
  8. Boudou P, Ibrahim F, Cormier C, et al. Third- or second-generation parathyroid hormone assays: a remaining debate in the diagnosis of primary hyperparathyroidism. J Clin Endocrinol Metab 2005; 90:6370.
  9. Carnevale V, Dionisi S, Nofroni I, et al. Potential clinical utility of a new IRMA for parathyroid hormone in postmenopausal patients with primary hyperparathyroidism. Clin Chem 2004; 50:626.
  10. Endres DB, Villanueva R, Sharp CF Jr, Singer FR. Immunochemiluminometric and immunoradiometric determinations of intact and total immunoreactive parathyrin: performance in the differential diagnosis of hypercalcemia and hypoparathyroidism. Clin Chem 1991; 37:162.
  11. Nussbaum SR, Zahradnik RJ, Lavigne JR, et al. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 1987; 33:1364.
  12. Silverberg SJ, Shane E, de la Cruz L, et al. Skeletal disease in primary hyperparathyroidism. J Bone Miner Res 1989; 4:283.
  13. Fuleihan GE, Gundberg CM, Gleason R, et al. Racial differences in parathyroid hormone dynamics. J Clin Endocrinol Metab 1994; 79:1642.
  14. Grant FD, Conlin PR, Brown EM. Rate and concentration dependence of parathyroid hormone dynamics during stepwise changes in serum ionized calcium in normal humans. J Clin Endocrinol Metab 1990; 71:370.
  15. Hollenberg AN, Arnold A. Hypercalcemia with low-normal serum intact PTH: a novel presentation of primary hyperparathyroidism. Am J Med 1991; 91:547.
  16. Au AY, McDonald K, Gill A, et al. PTH mutation with primary hyperparathyroidism and undetectable intact PTH. N Engl J Med 2008; 359:1184.
  17. Silverberg SJ, Shane E, Jacobs TP, et al. Nephrolithiasis and bone involvement in primary hyperparathyroidism. Am J Med 1990; 89:327.
  18. El-Hajj Fuleihan G, Brown EM. Familial Hypocalciuric Hypercalcemia and Neonatal Severe Hyperparathyroidism. In: The Parathyroids, 3rd ed, Bilezikian JP, Marcus R, Levine MA, et al (Eds), Elsevier, London 2014. p.365.
  19. Fuleihan Gel-H. Familial benign hypocalciuric hypercalcemia. J Bone Miner Res 2002; 17 Suppl 2:N51.
  20. Marx SJ, Stock JL, Attie MF, et al. Familial hypocalciuric hypercalcemia: recognition among patients referred after unsuccessful parathyroid exploration. Ann Intern Med 1980; 92:351.
  21. Marx SJ. Letter to the editor: Distinguishing typical primary hyperparathyroidism from familial hypocalciuric hypercalcemia by using an index of urinary calcium. J Clin Endocrinol Metab 2015; 100:L29.
  22. Christensen SE, Nissen PH, Vestergaard P, et al. Discriminative power of three indices of renal calcium excretion for the distinction between familial hypocalciuric hypercalcaemia and primary hyperparathyroidism: a follow-up study on methods. Clin Endocrinol (Oxf) 2008; 69:713.
  23. Broadus AE, Horst RL, Lang R, et al. The importance of circulating 1,25-dihydroxyvitamin D in the pathogenesis of hypercalciuria and renal-stone formation in primary hyperparathyroidism. N Engl J Med 1980; 302:421.
  24. Silverberg SJ, Shane E, Jacobs TP, et al. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 1999; 341:1249.
  25. El-Hajj Fuleihan G, Heath H III. Familial benign hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. In: The Parathyroids: Basic and Clinical Concepts, 2nd, Bilezikian JP, Marcus R, Levine MA (Eds), Academic Press, San Diego 2001. p.607.
  26. Nissen PH, Christensen SE, Heickendorff L, et al. Molecular genetic analysis of the calcium sensing receptor gene in patients clinically suspected to have familial hypocalciuric hypercalcemia: phenotypic variation and mutation spectrum in a Danish population. J Clin Endocrinol Metab 2007; 92:4373.
  27. Bilezikian JP, Brandi ML, Eastell R, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 2014; 99:3561.
  28. Berger AD, Wu W, Eisner BH, et al. Patients with primary hyperparathyroidism--why do some form stones? J Urol 2009; 181:2141.